Fortis appoints Arpwood Capital to advise on sale bids

New Delhi, May 4 : Fortis Healthcare today said it has appointed Arpwood Capital Private Ltd to advise the board on various sale bids.

The firm will act as financial advisor to the board to provide its independent opinion on the offers received or to be received from bidders for a potential significant equity investment and/or acquisition or restructuring of its assets, and on the appropriateness of the process put into place for dealing with the said offers, the healthcare major said in a regulatory filing.

Arpwood Capital Pvt Ltd is an investment banking firm engaged in providing merger, acquisition and capital raising advisory services.

Fortis Healthcare board is scheduled to meet on May 10 to take a decision on the binding bids for the company as recommended by the expert advisory committee (EAC).

Fortis Healthcare has already received binding offers from four entities – KKR-backed Radiant Life Care, IHH Healthcare, Manipal/TPG consortium, and Munjal and Burman family offices.

The fifth bidder, Fosun Health Holdings, an arm of Fosun International, which made a non-binding proposal to invest a total of USD 350 million (over Rs 2,295 crore) at a price up to Rs 156 per share, has so far not revised its offer. MSS SBT SBT

  • Related Posts

    Yashoda Medicity’s Medical Tourism Footprint widens with Republic of Kazakhstan on Board

    MOU signed for Patient Referrals, Tele-Consultations and Specialist Healthcare Collaboration Delhi NCR: Unveiled not long ago, Yashoda Medcity’s reputation as being best in class healthcare facility in Delhi NCR has…

    Liver enters FATal Straits in India, AIIMS Experts red flag

    In first for India, World Congress of Gastroenterology comes calling to asses GI disease burden New Delhi: As global and national burden of digestive diseases reach a critical crossroads, World…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre